NHS to lose out on new drugs, pharma firm warns

Novartis warns NHS may lose access to new drugs due to high costs, highlighting the impact of failed drug pricing deals between Health Secretary Wes Streeting and pharma firms. Novartis criticizes outdated approval methods for innovative drugs, calling the UK's healthcare market "largely uninvestable." The UK government's offer aimed to boost the pharmaceutical sector, but industry concerns persist over "uncompetitive and punitive rebates." The debate underscores the need for reform in drug evaluation processes to ensure patient access to cutting-edge treatments.